14 July 2026 Screener
3 new tickers (ALNY, APP, TRMB) cleared the 40%-off-high bar for the first time and got full diligence; existing log names got fresh-evidence-only checks. The mandatory 5-year valuation-history check (skipped 3 runs running) was finally executed.
New names, none actionable:
ALNY (Alnylam) — 6/10. Real RNAi moat, FCF just turned positive, cheapest 5yr valuation multiple in its history, but binary clinical-trial risk (CARDIO-TTRansform data due later this year) and no insider buying.
TRMB (Trimble) — 6/10. Cheapest 5yr valuation of the three, real ARR/subscription transition, but FCF is declining ($704M→$133M over 5 years) — genuine value-trap risk if it doesn’t stabilize.
APP (AppLovin) — 4/10, effectively rejected. Strong fundamentals but still expensive relative to its own history (~27x EV/Sales vs. 2-42x range) and carries an unresolved SEC probe plus active securities-fraud litigation from 2025 short-seller allegations.
Notable escalations: CMG and CRM both got fresh evidence (an independent 5-year valuation check found CRM 52% and CMG 32% below their own historical multiples) and moved to 2 appearances/Elevated. NFLX crossed to 3 appearances — technically hitting the “high-conviction repetition” threshold — but its conviction score is still only 6/10, below the 7/10 bar required to present it as an idea, so it’s not being surfaced as actionable. Its Q2 earnings on 7/16 is the swing event to watch.
Demoted: CPRT, CEG, and INTU all went a second consecutive run with no fresh evidence and were demoted back to Watchlist.
Macro: Backdrop escalated — a third night of US strikes on Iran, a formal US naval blockade of Iranian ports took effect today, oil had its biggest one-day jump since April, and Oracle’s credit was cut to BBB- with new commentary tying the Apple v. OpenAI lawsuit to Oracle’s counterparty risk (reaffirms its existing rejection).
This is research and screening output only, not a trade instruction — worth doing your own diligence before acting on anything here.